Aurisco Pharmaceutical Co.,Ltd

Pregabalin may look a simple molecule, but for patients, having an off-patent alternative to Lyrica® with consistent high quality makes all the difference! Ensuring Safety, Quality, Compliance, Low-Cost and Sustainability means working with Aurisco, an USFDA inspected API manufacturer. 👉Contact us for more information: 📧info@aurisco.com📧 #Pregabalin #Lyrica #Generics #pharma #affordablehealthcare #patientsafety #sustainableprocurement

Tackling some challenging chemistries, we develop and manufacture sustainable and competitive high quality active ingredients for generic and innovative pharmaceutical applications. On the first 3 quarters of 2024 we have filled 4 DMFs in the US, enabling our customers to develop their ANDAs and 505(b)2 applications with confidence. For more information contact us at info@aurisco.com #Brivaracetam #Relugolix #Apalutamide #Vibegron #generics #pharma #affordablehealthcare #pharmaceuticals #genericdevelopment #APIs

Aurisco will exhibit at TIDES Europe in Hamburg. Visit our Stand 411and find out about our latest capacity expansion in Oligonucleotide cGMP Manufacturing, Recombinant Peptides and SPPS. #TIDES #TIDESEurope #Peptides #Oligonucleotides #Oligos #GLP1 #Semaglutide #Tirzepatide #Nusinersen #Inclisiran #GalNAc

📢Aurisco announces another important milestone in its journey towards carbon neutrality. As part of our ISO14064 we report the Greenhouse Gas (GHG) emissions from our Aurisco Pharmaceutical Co., Ltd site and reconfirm our commitment to reduce our carbon footprint, to become carbon neutral by 2027. #Sustainability #Pharma #sustainableprocurement #ISO14064

It takes a team of dedicated professionals to bring the best products to market and that is what you will find at Aurisco. We thank all our customers and business partners for their visits at CPhI Stand 1B50 and wish you a safe return home. #CPhI #CPhIMilan #CPhI2024

CPhI day 2 and we're having great feedback from our customers and interesting business development opportunities. Come over to stand 1B50 and check the latest news on our products and technologies. #CPhI #CPhI2024 #CPhIMilan

Sourcing Vibegron for your generic development program is becoming easier. Aurisco is a specialist in sustainable manufacturing of complex molecules with cGMP inspected manufacturing sites and over 26 years of track record. We can help you! Meet us at CPhI - Stand 1B50. #vibegron #generic #affordablehealthcare #generics #pharma #CPhI Products protected by valid patents are for laboratory analytical/research purposes only and are not offered for sale in countries or areas where the sale of such products constitutes a patent infringement. Any liability is at buyer's risk.

CPhI is a unique opportunity to meet customers and suppliers, colleagues and long time pharma-friends! Aurisco's stand is at 1B50. That's why CPhI is where pharma meets!

Join the crowd of pharma procurement professionals that have found the right API partner for their complex generic development programs. Meet us at CPhI Stand 1B50 and understand why they are happy to work with us! #CPhI #generics #peptides #semaglutide #GLP1 Products protected by valid patents are for laboratory analytical/research purposes only and are not offered for sale in countries or areas where the sale of such products constitutes a patent infringement. Any liability is at buyer's risk.

Sourcing Relugolix for your generic development program is becoming easier. Did you know FDA will revise the Relugolix PSG to remove recommendations on fed BE study to align with ICH M13A? Aurisco is a specialist in steroids and hormones with cGMP inspected manufacturing sites and over 26 years of track record. We can help you! Meet us at CPhI - Stand 1B50. #Relugolix #generic #Orgovyx #prostatecancer #affordablehealthcare #menhealth #generics #pharma #CPhI ORGOVYX (Relugolix) was the first orally-administered gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the FDA for the treatment of advanced prostate. ICH Guideline M13A is a Scientific guideline on bioequivalence for immediate-release solid oral dosage forms. Products protected by valid patents are for laboratory analytical/research purposes only and are not offered for sale in countries or areas where the sale of such products constitutes a patent infringement. Any liability is at buyer's risk.